When you type the query "star share price" into a financial search engine, you are often met with an overwhelming and confusing array of stock charts, news articles, and ticker symbols. In global equity markets, "Star" is a highly popular brand and corporate name shared by multiple major publicly traded companies operating in completely different sectors, regions, and regulatory environments. From the global generic pharmaceutical leader Strides Pharma Science (traded under the ticker symbol STAR on the National Stock Exchange of India) to the country's dominant standalone private medical insurer Star Health and Allied Insurance Company (NSE: STARHEALTH), and even Australia's embattled hospitality and gaming giant The Star Entertainment Group (ASX: SGR), each stock presents a drastically different investment thesis, financial risk profile, and future growth trajectory.

This comprehensive investor's guide is designed to deconstruct the "star share price" search. We will untangle the confusion by diving deep into the financial performance, latest quarterly and full-year FY26 earnings results, growth catalysts, risk factors, and institutional price targets for each major "STAR" ticker. Whether you are searching for defensive healthcare growth, high-yielding dividend plays, secular insurance penetration, or high-risk contrarian turnaround opportunities, this expert analysis will provide you with the actionable insights needed to position your portfolio strategically in 2026.

Strides Pharma Science Ltd (NSE: STAR) — Riding the Generic Wave

Current Market Overview & Live Stock Price Dynamics

Strides Pharma Science Limited, headquartered in Bengaluru, India, is one of the premier pharmaceutical formulations companies trading under the prominent ticker symbol STAR on the National Stock Exchange (NSE) and BSE code 532531. As of late May 2026, the company’s share price is trading in a steady range between ₹1,154 and ₹1,185. This current valuation represents a remarkable recovery from its 52-week low of ₹680, although it remains slightly below its 52-week high of ₹1,231. With a robust market capitalization hovering around ₹10,922 crore, Strides Pharma has solidified its position as a high-performing mid-cap stock in the Indian healthcare landscape. The company has rewarded long-term investors handsomely over the past year, achieving an annual return exceeding 61% through disciplined financial execution and structural corporate changes.

Key Takeaways from the FY26 Financial Performance

In May 2026, Strides Pharma Science released its consolidated financial results for the full fiscal year 2025-26, highlighting a period of sustained operational excellence. The company reported a total consolidated revenue of ₹4,858.70 crore, representing a year-on-year growth of 6.4%. More impressively, Strides saw its consolidated EBITDA rise by 15.3% YoY to reach ₹925.30 crore, translating to an EBITDA margin expansion to 19.0%—an improvement driven by a shift in focus toward high-margin, complex generic formulations.

The company's operational Profit After Tax (PAT) witnessed a phenomenal surge, climbing 50.3% to ₹390.40 crore (with standalone PAT at ₹183.63 crore). Reflecting this solid financial health, the Board of Directors recommended a final dividend of ₹5 per share for the fiscal year. Key financial leverage metrics also improved dramatically, with the company's Net Debt to EBITDA ratio dropping to 1.55x from 1.9x in the prior year, while its Return on Capital Employed (ROCE) expanded to a healthy 15.8%.

The Strategic Demerger of OneSource Specialty Pharma

For investors closely tracking the STAR share price, the most significant corporate event in recent history has been the successful demerger of its Contract Development and Manufacturing Organisation (CDMO) and soft gelatin business into a newly formed entity: OneSource Specialty Pharma Limited (formerly Stelis Biopharma). This scheme of arrangement received NCLT and regulatory clearances, culminating in the separate public listing of OneSource in January 2025.

Under the share-swap structure, Strides Pharma shareholders received 1 fully paid-up share of OneSource Specialty Pharma (valued at a face value of ₹1) for every 2 shares held in Strides. This demerger was a masterstroke in corporate restructuring. It effectively unlocked massive value for existing shareholders while allowing the parent company, Strides Pharma, to operate as a lean, focused formulations player. Meanwhile, OneSource is positioned to capture a massive market share in the global CDMO boom—specifically capitalizing on high-complexity drug-device combinations, sterile injectables, and the multi-billion-dollar GLP-1 (semaglutide) weight-loss drug patent cliff. While OneSource is now a separately traded stock, its corporate pedigree remains tightly linked to Strides, heavily influencing positive market sentiment around the STAR ticker.

Operational Growth Drivers and Future Outlook

Looking ahead into FY27, Strides Pharma Science has several strong growth catalysts in place. The company’s ex-US business has been a major highlight, surging 21% YoY in revenue. This growth has been spearheaded by robust expansion in highly regulated markets across Europe, Australia, and Canada, where Strides' IP-led product licensing models have gained significant traction. In the highly competitive United States market, the company's performance has remained resilient, successfully navigating typical seasonal fluctuations and competitive pricing pressures.

Furthermore, Strides completed a successful US FDA inspection at its flagship Bangalore facility in mid-May 2026, receiving minor observations that have already been addressed. This regulatory clearance paves the way for a steady stream of new Abbreviated New Drug Application (ANDA) approvals. As the company continues to optimize capacity utilization, expand its leading position in soft gelatin capsule manufacturing, and pare down debt, analysts project a highly favorable trajectory. The consensus share price target for Strides Pharma (STAR) in 2026 stands around ₹1,264, indicating a potential double-digit upside from current levels.

Star Health & Allied Insurance Co. Ltd (NSE: STARHEALTH) — Dominating the Health Insurance Sector

Stock Performance and Post-Earnings Surge

Another dominant entity capturing investor attention under the "star share price" banner is Star Health and Allied Insurance Company Limited (NSE: STARHEALTH | BSE: 543412). As India’s first standalone health insurance provider, Star Health is a massive financial services player with a market cap exceeding ₹30,800 crore. In late May 2026, the STARHEALTH stock is trading at approximately ₹524 to ₹533 per share.

The stock experienced a dramatic 13.3% single-day intraday surge to ₹586.25 in late April 2026, immediately following the announcement of its blockbuster fourth-quarter (Q4 FY26) financial results. This rally provided a major relief to shareholders, lifting the stock well above its 52-week low of ₹412.60. The massive post-earnings breakout demonstrated strong institutional demand and restored confidence in the company's ability to maintain its market leadership amidst aggressive competition from multi-line insurers.

Decoding the Landmark FY26 Balance Sheet and Premium Growth

Star Health’s FY26 financial scorecard highlights why it remains the undisputed king of private retail health insurance in India. The company reported a historic Gross Written Premium (GWP) of ₹20,369 crore, representing a 16% YoY increase. This premium growth was heavily driven by the retail health insurance segment, which has seen unprecedented demand due to rising healthcare costs and growing financial literacy across tier-2 and tier-3 Indian cities.

For the full fiscal year, Star Health's Profit After Tax (PAT) rose to ₹911 crore, marking a solid 16% increase compared to the previous year. Most notably, the company's Q4 FY26 standalone net profit surged to ₹111.34 crore, compared to a mere ₹51 lakhs in the corresponding quarter of the previous year. This massive profitability jump was achieved through a multi-pronged approach: improved underwriting discipline, a significantly lower claims loss ratio, enhanced operating efficiencies, and robust customer renewal rates. The company's total income from operations for FY26 reached ₹18,621.92 crore, up from ₹16,781.36 crore in the prior fiscal year, proving that the insurer is successfully scaling its revenue base while keeping claim costs in check.

Long-Term Growth Catalysts and Target Price Analysis

Star Health's long-term growth story is underpinned by structural tailwinds in the Indian economy. With a market share of roughly 15.8% in the overall Indian health insurance space and an even higher share in the highly lucrative retail health segment, the company possesses a strong moat. Its distribution network is unparalleled, comprising over 15,800 employees, hundreds of branch offices, and an extensive network of individual agents who act as the primary engines for retail customer acquisition.

Two key catalysts are poised to accelerate Star Health's growth in 2026 and beyond. First, the industry is witnessing a strong push for GST rationalization or exemption on health insurance premiums, a policy shift that would immediately lower the cost of policies for retail consumers and trigger a massive wave of new signups. Second, Star Health is aggressively expanding its bancassurance channel, forging strategic tie-ups with leading private and public sector banks to cross-sell policies to their vast customer bases.

Major brokerages, including Motilal Oswal and Emkay, have issued positive outlooks for STARHEALTH following its FY26 earnings. The consensus average share price target stands at ₹587 to ₹667, with optimistic targets extending up to ₹700. Investors looking for a high-quality financial stock with a defensive, domestic-growth orientation often view Star Health as a cornerstone portfolio asset.

The Star Entertainment Group Ltd (ASX: SGR) — Turnaround Prospect or Value Trap?

The Regulatory Storm and Corporate Restructuring

For international investors searching for "star share price," the query might lead them to the Australian Securities Exchange (ASX), where The Star Entertainment Group Limited (ASX: SGR) trades. SGR is a major casino, resort, and hospitality operator in Australia, managing iconic complexes such as The Star Sydney, The Star Gold Coast, and Treasury Brisbane. However, unlike its Indian counterparts, SGR's recent history has been defined by immense regulatory stress, corporate governance failures, and severe financial pain.

As of late May 2026, SGR's share price is trading as a highly speculative penny stock at approximately A$0.10, down more than 90% from its historical multi-dollar highs. SGR’s collapse was precipitated by successive independent regulatory inquiries (the Bell Inquiries in New South Wales and similar reviews in Queensland) which revealed systematic breaches of anti-money laundering (AML) and counter-terrorism financing (CTF) laws, alongside failures in responsible gambling practices. These findings resulted in massive financial penalties, the suspension of casino licenses, and the installation of government-appointed managers to oversee daily operations. The severe financial damage forced SGR to write down billions in asset values, suspend its dividend payouts, and enter intensive negotiations with creditors to prevent insolvency.

Queen's Wharf Brisbane: The Billion-Dollar Savior?

Despite its current distressed status, SGR's ultimate survival and turnaround thesis rest almost entirely on its marquee joint-venture development: the massive $3.6 billion Queen's Wharf Brisbane precinct. Developed in partnership with Chow Tai Fook Enterprises and Far East Consortium, this world-class destination represents one of the largest tourism and hospitality infrastructure projects in Australian history.

The staged opening of Queen's Wharf and its flagship venue, The Star Brisbane, has begun in phases. Once fully operational, this integrated resort is expected to deliver a massive boost to Queensland’s tourism, creating thousands of jobs and generating predictable, high-volume cash flows. If SGR can successfully scale operations at Queen's Wharf while maintaining stable revenues at its Sydney and Gold Coast casinos, the company's financial profile could undergo a dramatic recovery, paving the way for debt reduction and eventual return to profitability.

Is SGR Stock Worth the High Risk?

At its current price of A$0.10, SGR represents a textbook high-risk contrarian bet. With a market capitalization of roughly A$663 million, the stock is priced for near-insolvency, meaning any positive regulatory or operational surprise could trigger an explosive rally. The company has also overhauled its leadership, bringing in experienced casino executives like Janelle Campbell (CEO of The Star Sydney) and Daniel Finch (CEO of The Star Brisbane) to rebuild trust with regulatory bodies.

However, conservative investors must exercise extreme caution. The company is burning through cash, carrying substantial debt, and faces ongoing class-action lawsuits and regulatory oversight. SGR remains a highly volatile value trap for standard portfolios, suitable only for speculative investors who are willing to wager on a multi-year, regulatory-approved corporate resurrection.

Key Differences & Comparison Table of "STAR" Stocks

Distinguishing Tickers and Preventing Trading Mistakes

Because search engines frequently group search queries based on text matches rather than financial context, retail investors often make the critical mistake of viewing financial charts for the wrong company. For example, a trader intending to buy shares of Strides Pharma Science (NSE: STAR) might accidentally look up the price chart for Star Health (NSE: STARHEALTH) or Star Energy Group (LSE: STAR) in the UK.

To avoid expensive errors, always cross-reference the ticker symbol, the country of origin, and the specific exchange (such as the National Stock Exchange of India, Bombay Stock Exchange, or Australian Securities Exchange) before placing any buy or sell orders. Below is an updated comparative overview of the major "STAR" stocks as of May 2026.

Investor Playbook: How to Position Your Portfolio

Sector-Specific Valuation Methodologies

Investing in these three companies requires completely different analytical frameworks. There is no one-size-fits-all approach when evaluating a pharmaceutical manufacturer, a health insurer, and an integrated casino resort.

• Strides Pharma (NSE: STAR): This stock should be evaluated based on pharmaceutical metrics, such as Enterprise Value to EBITDA (EV/EBITDA) multiples, the rate of US FDA approvals (ANDA pipeline), and Research & Development (R&D) spend. The successful demerger of its CDMO arm into OneSource has made Strides a pure formulations play, meaning its future value is highly dependent on international generic drug distribution and margin expansion in regulated markets.
• Star Health (NSE: STARHEALTH): The health insurance business must be analyzed using insurance-specific indicators, including the Combined Ratio (the measure of underwriting profitability calculated by taking the sum of incurred losses and operating expenses and dividing them by earned premiums), the Incurred Claims Ratio (ICR), and Gross Written Premium (GWP) growth. Since insurers hold massive cash reserves (or 'float') before claims are paid, their investment income yields are also highly sensitive to central bank interest rate movements.
• The Star Entertainment (ASX: SGR): As a distressed asset, SGR cannot be valued using traditional P/E ratios. Instead, investors must analyze its liquidity runway, debt-to-equity ratios, covenants, asset liquidation values, and political risk. The stock’s movement is highly correlated with regulatory announcements, state licensing decisions, and the phased EBITDA generation of the Queen’s Wharf project.

Macroeconomic Tailwinds and Headwinds

Beyond individual corporate metrics, broader macroeconomic environments play a decisive role in shaping the share prices of these companies in 2026. For Indian stocks like Strides Pharma and Star Health, India’s secular economic growth, rising disposable incomes, and increasing health awareness serve as structural tailwinds. In contrast, SGR in Australia is heavily exposed to consumer discretionary spending patterns, local interest rate cycles, and stringent anti-money laundering regulatory crackdowns that act as persistent headwinds.

Frequently Asked Questions (FAQs)

Q1: Why is there confusion when searching for "star share price"?

The search query "star share price" is highly ambiguous because several major publicly traded companies utilize "Star" in their name or ticker symbol. These include Strides Pharma Science (NSE: STAR), Star Health and Allied Insurance (NSE: STARHEALTH), and The Star Entertainment Group (ASX: SGR). To get the correct price and data, you must search using the exact ticker symbol on your trading platform.

Q2: What are the key details of Strides Pharma's (NSE: STAR) recent FY26 results?

Strides Pharma reported a strong performance for FY26. Consolidated revenue grew by 6.4% YoY to ₹4,858.70 crore, while consolidated EBITDA reached ₹925.30 crore, showing a 15.3% growth. The Board recommended a dividend of ₹5 per share, and the company's Net Debt to EBITDA improved to 1.55x, reflecting solid balance sheet deleveraging.

Q3: How did the OneSource demerger impact Strides Pharma's shareholders?

The demerger of Strides' CDMO and softgel business into OneSource Specialty Pharma was completed in late 2024, with OneSource listing in January 2025. Strides shareholders received 1 share of OneSource for every 2 shares of Strides they held. This demerger unlocked significant corporate value and allowed Strides to focus purely on high-margin generic drug formulations.

Q4: Why did the Star Health (STARHEALTH) share price surge in late April 2026?

Star Health's share price surged up to 13.3% following the announcement of its Q4 FY26 results. The insurer reported a massive jump in Q4 net profit to ₹111 crore and a full-year FY26 net profit of ₹911 crore (up 16% YoY). This explosive profitability was driven by a 16% growth in Gross Written Premium (GWP) to ₹20,369 crore, combined with better underwriting efficiency.

Q5: Is Star Entertainment Group (ASX: SGR) a safe investment at A$0.10?

No, SGR is currently a highly speculative, distressed penny stock. While it represents a classic turnaround candidate due to its multi-billion-dollar Queen's Wharf Brisbane project, the company faces severe regulatory compliance burdens, heavy debt, class-action lawsuits, and ongoing oversight. It should only be approached by investors with a very high risk tolerance.

Conclusion

Navigating the "star share price" landscape requires careful differentiation. Strides Pharma Science (NSE: STAR) represents a robust, lean, and highly profitable generic drug manufacturer that has successfully unlocked shareholder value via the OneSource CDMO demerger. Star Health (NSE: STARHEALTH) continues to command a powerful moat as India’s leading standalone health insurer, exhibiting stellar retail premium growth and underwriting discipline. Meanwhile, The Star Entertainment Group (ASX: SGR) is an embattled Australian resort operator trading at penny-stock levels, offering a speculative turnaround bet tied to its massive Queen’s Wharf Brisbane development.

By understanding the unique catalysts, ticker distinctions, and financial metrics of each stock, investors can make highly informed capital allocation decisions. Whether seeking defensive pharmaceutical growth, secular insurance penetration, or high-risk turnaround gains, the "STAR" universe has an asset class suited to every risk profile. Ensure you double-check the ticker symbol, monitor quarterly regulatory filings, and align your investments with your long-term portfolio objectives.